Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue. Management to Host ...
Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National ...
New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization. SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve ...
TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company is supporting partners and ...
LAVA-1266 is a potent bi-specific, T cell engager (bsTCE) that targets CD123+ tumor cells with Vγ9Vδ2-T cells using LAVA’s Gammabody ® platform. The bsTCE was designed to lyse CD123+ tumor cells with ...
Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with both the Nasdaq minimum bid price rule and Nasdaq’s periodic financial reporting rule.” As the ...
Oryzon has been invited to participate at the 8th Sachs Annual Neuroscience Innovation Forum, which will be held on January 12 at the Marines’ Memorial Club in San Francisco (USA). The company will ...
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
scPharmaceuticals expects preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of $12 million to $12.3 million, representing a 22% increase from the third quarter of 2024 at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback